

# HIV, Aging, and COVID-19 Intersecting Pandemics

Sarah Schmalzle MD, FIDSA sschmalzle@ihv.umaryland.edu February 21, 2023





#### **Disclosures**








Sources: U.S. Bureau of the Census





Geriatricians

# **Epidemiology: Aging**




Post-Gazette

US Census Bureau; NRMP.org/match-data-analytics/fellowship-data-reports/, HRSA: National and Regional Projections of Supply and Demand for Geriatricians 2013-2025





# Epidemiology: HIV



CCBY


#### Our World in Data





the


#### Intersection: HIV and Aging





#### Intersection: HIV, Aging, Comorbidity and Multi-morbidity

- Cardiovascular disease: HTN, CHD, AMI, CHF, A fib, PAD, CVA
- Low bone mineral density,
  osteonecrosis
- Renal disease
- Liver disease
- Diabetes
- Cancers
  - <u>AIDS defining</u>: non-Hodgkin lymphoma, Kaposi sarcoma, cervical
  - <u>Non-AIDS defining</u>: Hodgkin lymphoma ,lung, liver, anal, oral/pharynx
- Neurocognitive deficits
- Frailty



Freiberg. JAMA Intern Med. 2013;173(8):614-622. Butt AA. Arch Intern Med 2011. Hsu JC. J Am Coll Cardiol 2013. National Cancer Institute. HIV Infection and Cancer Risk Islam FM. HIV Medicine 2012. Schouten. CID 2014;59(12):1787-97 Chow FC. JAIDS 2012. Falade-Nwulia O. Sex Health 2011;8(4):512-20

theTH





#### Intersection: HIV, Social Isolation, and Loneliness

- >  $\frac{1}{2}$  depression
- ~ 1/3 other MH diagnosis
- > ½ lack social support
- ~ 1/3 to  $\frac{1}{2}$  loneliness or isolation
- >  $\frac{1}{2}$  daily substance use
- >  $\frac{1}{2}$  stigma/discrimination
  - $\sim \frac{1}{4}$  ageism
  - $\sim \frac{1}{4}$  homophobia




Depression Alcohol use Tobacco use Less relationships Lower QOL Higher costs (CVD, CVA) <u>Mortality</u>

HealthHIV's Inaugural State of Aging With HIV National Survey. 2020. Greene M. AIDS Behav 2019;22(5):1475-84. https://healthhiv.org/programs/healthhivs-pozitively-aging Marziali ME. AIDS Behav 2020:1-12.






# **COVID-19 Outcomes Related to HIV** (and aging and comorbidities in PLWH)












#### Risk factors for poor COVID-19 outcomes











#### **COVID-19 and Age and Comorbidities**



COVID-19 Death Risk Ratio (RR) for Select Age Groups and Comorbid Conditions

https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html








### COVID-19 Outcomes in PLWH – WHO data


- 24 countries with HIV data (mostly US, S Africa)
- 168,649 hospitalized patients
- 15,222 HIV + (92% on ART)

- PLWH Comorbidities:
- HTN 33%, Diabetes 23%, Obesity 16%
- TB 13%, CKD 12%, CLD 12%, smoking 9%



Bertagnolio IAS 2021; 2498








## COVID-19 Outcomes in PLWH – by CD4 and HIV VL

| Outcome            | Clinical Characteristics            | Odds ratio (95% CI) | <i>P</i> value |
|--------------------|-------------------------------------|---------------------|----------------|
| Hospitalization    | Age, years                          | 1.04 (1.01–1.08)    | .01            |
|                    | CD4 count                           |                     |                |
|                    | <200 cells/mm <sup>3</sup>          | 5.22 (1.28–21.35)   | .02            |
|                    | 200–500 cells/mm <sup>3</sup>       | 1.47 (.7–3.08)      | .30            |
|                    | >500 cells/mm <sup>3</sup>          | 1.00 (reference)    |                |
|                    | HIV with no other known comorbidity | 1.00 (reference)    |                |
|                    | HIV with 1 or 2 comorbidities       | 1.19 (.56–2.55)     | .65            |
|                    | HIV with 3 or more comorbidities    | 4.56 (1.81–11.48)   | <.01           |
| Severe<br>outcomeª | Age, years                          | 1.04 (1.01–1.07)    | .02            |
|                    | CD4 count                           |                     |                |
|                    | <200 cells/mm <sup>3</sup>          | 3.32 (1.11–9.93)    | .03            |
|                    | 200–500 cells/mm <sup>3</sup>       | 1.75 (.76–4.02)     | .19            |
|                    | >500 cells/mm <sup>3</sup>          | 1.00 (reference)    |                |
|                    | HIV with no other known comorbidity | 1.00 (reference)    |                |
|                    | HIV with 1 or 2 comorbidities       | 2.58 (.56–11.91)    | .23            |
|                    | HIV with 3 or more comorbidities    | 5.09 (1.05–24.76)   | .04            |
|                    |                                     |                     |                |

#### 286 HIV+ patients with COVID

Dandachi D, Clin Inf Dis 2021;73





# Risk factors for poor **response** to public health measures

Poverty, food insecurity

Marginal employment

Low educational attainment

Social isolation

Loneliness

Lack of social support

Struggles with ADLs

Substance use


Mental illness

Incarceration






## Effect of COVID-19 Pandemic on HIV Care Delivery








# the THRIVE program

# HIV Testing during COVID-19 Pandemic - US









Curanovic IAS 2021; Moitra Lancet Reg Health 2022








### HIV RNA tests/ month








the

program

#### HIV care engagement through the COVID-19 pandemic



Mayer IDWeek 2020













**Possible solutions** 

- Safe(r) in-person visits
- Meeting medical needs outside of in-person visits
- Meeting patient resource needs
- Meeting patients mental and behavioral health needs
- Addressing COVID-19 stigma
- Vaccination!




- Transition to telemedicine
- Revision of staff roles
- Repurposing of funding
- Reliance on local resources





# Safe(r) in-person visits

- Limited appointments by patient type
- Spaced out appointments
- Limited appointments per day
- Physical distancing within the clinical space
- Discourage walk ins, loitering
- Pre-visit and front door symptom screenings










#### Meeting medical needs outside of in-person visits

- Comprehensive geriatric assessment
- Telemedicine / telework
- Home monitoring
- Outside laboratories
- Pharmacy: extended and synchronized refills, home delivery, medication reconciliation, BP management
- Social work, law: advanced care planning









# Meeting patient resource needs

- Food
- Personal care items
- Transportation
- Telemedicine support








Meeting patients mental and behavioral health needs

- Make telemedicine visit as 'normal' as possible
- Connection with support system
- Collaborative care mental health model
- Virtual support groups
- Adjustment of buprenorphine maintenance
  program







#### Vaccination



UNIVERSITY of MARYLAND SCHOOL OF MEDICINE



theTHRIVE

Have questions about the COVID-19 vaccine? If so, schedule a telemed visit with a THRIVE pharmacist to Is it safe? get your questions ✓ What are the side effects? answered!! Should I get the vaccine? Am I in a high risk group? When is it my turn? UNIVERSITY of MARYLAND MEDICAL CENTER the Reaching, Inspiring, to achieve Victory over program illness, and Embrace life Made with PosterMvWall.com





# COVID-19 Fear, Stigma, & Resilience


- Fear & Stigma
  - "The virus"
  - Repeated requests for testing without exposure
  - Patients turned away due to prior + testing
  - Delayed or missed medical care
- Resilience
  - Strict compliance with CDC recommendations
  - "It is what it is"



theTH







## Summary

- PLWH are PAWH and OAWH (aging & older)
  - New models of geriatric care needed
- Poor COVID outcomes:
  - Age
  - Comorbidities prevalent in HIV/ OAWH
  - HIV alone (worse with low CD4)
- During pandemic:
  - Lower HIV screening
  - Less HIV monitoring
  - Same suppression rates and overall visits
- OAWH at risk for poor social outcomes also
  - Can be partially mitigated with shifting model